Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus

被引:41
作者
Caumes, E
Guermonprez, G
Lecomte, C
Katlama, C
Bricaire, F
机构
[1] Serv. des Maladies I., Hop. Pitie-Salpetriere, Paris
关键词
D O I
10.1001/archderm.133.4.465
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: To study the safety and efficacy of desensitization with the use of a combination product of sulfamethoxazole and trimethoprim in previously hypersensitive patients infected with the human immunodeficiency virus. Design: Prospective survey, with a median follow-up of 16 months (range, 5-24 months). Setting: Day-care hospital in a referral center. Patients: All human immunodeficiency virus-infected patients who had a history of allergic reactions leg, rash) to sulfamethoxazole-trimethoprim and who required sulfamethoxazole-trimethoprim prophylaxis. Intervention: The desensitization procedure took 2 days. The full dose (sulfamethoxazole-trimethoprim, 400-80 mg) was reached on the third day according to the following schedule: day 1-4-0.8 mg at 9 AM, 8-1.6 mg at 11 AM, 20-4 mg at 1 PM, and 40-8 mg at 5 PM; day 2-80-16 mg at 9 AM, 160-32 mg at 3 PM, and 200-40 mg at 9 PM; and day 3-400-80 mg at 9 AM. Main Outcome Measurer The onset of cutaneous adverse effects attributable to sulfamethoxazole-trimethoprim therapy within 3 months after desensitization. Results: Of the 48 evaluable patients, 37 (77%) tolerated sulfamethoxazole-trimethoprim desensitization without toxic effects and continued to take sulfamethoxazole-trimethoprim daily. Desensitization failed in 11 cases (5 on day 1, 3 on day 2, and 1 each on days 9, 11, and 90). Acute hypotension and a nonfatal myocardial infarction developed in 1 of these patients. The factors that were predictive of failure were a relatively high CD4(+) cell percentage (11% vs 8%; P=.008) and a relatively high CD4(+)/CD8(+) ratio (0.27 vs 0.12; P=.02). Conclusions: The efficacy of desensitization with sulfamethoxazole-trimethoprim was confirmed; this desensitization procedure was more often Successful in patients with lower CD4(+) cell percentages and CD4(+)/CD8(+) ratios. However, sulfamethoxazole-trimethoprim therapy should be reintroduced carefully.
引用
收藏
页码:465 / 469
页数:5
相关论文
共 21 条
[1]   DESENSITIZATION TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN HIV-INFECTED PATIENTS [J].
ABSAR, N ;
DANESHVAR, H ;
BEALL, G .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 93 (06) :1001-1005
[2]  
BACHMEYER C, 1995, AIDS, V9, P299, DOI 10.1097/00002030-199509030-00013
[3]  
BISSUEL F, 1995, AIDS, V9, P407, DOI 10.1097/00002030-199509040-00021
[4]   CLINICAL AND LABORATORY MARKERS OF HYPERSENSITIVITY TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN PATIENTS WITH PNEUMOCYSTIS-CARINII PNEUMONIA AND AIDS [J].
CARR, A ;
SWANSON, C ;
PENNY, R ;
COOPER, DA .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (01) :180-185
[5]   EFFICACY AND SAFETY OF RECHALLENGE WITH LOW-DOSE TRIMETHOPRIM SULFAMETHOXAZOLE IN PREVIOUSLY HYPERSENSITIVE HIV-INFECTED PATIENTS [J].
CARR, A ;
PENNY, R ;
COOPER, DA .
AIDS, 1993, 7 (01) :65-71
[6]   A life-threatening adverse reaction during trimethoprim-sulfamethoxazole desensitization in a previously hypersensitive patient infected with human immunodeficiency virus [J].
Caumes, E ;
Guermonprez, G ;
Winter, C ;
Katlama, C ;
Bricaire, F .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (06) :1313-1314
[7]   CURRENT STATUS OF PROPHYLAXIS FOR OPPORTUNISTIC INFECTIONS IN HIV-INFECTED PATIENTS [J].
DECKER, CF ;
MASUR, H .
AIDS, 1994, 8 (01) :11-20
[8]   RAPID ORAL DESENSITIZATION TO TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMZ) - USE IN PROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH AIDS WHO WERE PREVIOUSLY INTOLERANT TO TMP-SMZ [J].
GLUCKSTEIN, D ;
RUSKIN, J .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (04) :849-853
[9]   A CONTROLLED TRIAL OF TRIMETHOPRIM SULFAMETHOXAZOLE OR AEROSOLIZED PENTAMIDINE FOR SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - AIDS CLINICAL-TRIALS GROUP PROTOCOL-021 [J].
HARDY, WD ;
FEINBERG, J ;
FINKELSTEIN, DM ;
POWER, ME ;
HE, W ;
KACZKA, C ;
FRAME, PT ;
HOLMES, M ;
WASKIN, H ;
FASS, RJ ;
POWDERLY, WG ;
STEIGBIGEL, RT ;
ZUGER, A ;
HOLZMAN, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (26) :1842-1848
[10]   PREDICTING CUTANEOUS HYPERSENSITIVITY REACTIONS TO COTRIMOXAZOLE IN HIV-INFECTED INDIVIDUALS RECEIVING PRIMARY PNEUMOCYSTIS-CARINII PNEUMONIA PROPHYLAXIS [J].
HENNESSY, S ;
STROM, BL ;
BERLIN, JA ;
BRENNAN, PJ .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1995, 10 (07) :380-386